Publicacions en què col·labora amb Pilar Llamas Sillero (16)

2024

  1. Age-Related Differences in the Presentation, Management, and Clinical Outcomes of 100,000 Patients With Venous Thromboembolism in the RIETE Registry

    Archivos de Bronconeumologia, Vol. 60, Núm. 3, pp. 143-152

  2. Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 8, pp. 2234-2246

  3. Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID-19 vaccine

    European Journal of Clinical Investigation

  4. Risk of recurrence after discontinuing anticoagulation in patients with COVID-19- associated venous thromboembolism: a prospective multicentre cohort study

    eClinicalMedicine, Vol. 73

  5. The prognostic value of blood cellular indices in pulmonary embolism

    American Journal of Hematology, Vol. 99, Núm. 9, pp. 1704-1711

  6. Venous thromboembolism characteristics and outcomes among RIETE patients tested and untested for inherited thrombophilia

    Blood Advances, Vol. 8, Núm. 18, pp. 4950-4959

2022

  1. Therapeutic versus Prophylactic Bemiparin in Hospitalized Patients with Nonsevere COVID-19 Pneumonia (BEMICOP Study): An Open-Label, Multicenter, Randomized, Controlled Trial

    Thrombosis and Haemostasis, Vol. 122, Núm. 2, pp. 295-299

2021

  1. Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis

    Journal of Thrombosis and Haemostasis, Vol. 19, Núm. 8, pp. 1981-1989

  2. Clinical characteristics and 3-month outcomes in cancer patients with incidental versus clinically suspected and confirmed pulmonary embolism

    European Respiratory Journal, Vol. 58, Núm. 1

  3. Timing and characteristics of venous thromboembolism after noncancer surgery

    Journal of Vascular Surgery: Venous and Lymphatic Disorders, Vol. 9, Núm. 4, pp. 859-867.e2

2019

  1. Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry

    Orphanet Journal of Rare Diseases, Vol. 14, Núm. 1

2017

  1. Development of a Risk Prediction Score for Occult Cancer in Patients With VTE

    Chest, Vol. 151, Núm. 3, pp. 564-571

  2. Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation

    American Journal of Medicine, Vol. 130, Núm. 4, pp. 482.e1-482.e9

2016

  1. Identification of new markers of recurrence in patients with unprovoked deep vein thrombosis by gene expression profiling: the retro study

    European Journal of Haematology, Vol. 97, Núm. 2, pp. 128-136

2008

  1. AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms

    Haematologica, Vol. 93, Núm. 5, pp. 729-734

2006

  1. Fixed-dose low-molecular-weight heparin, bemiparin, in the long-term treatment of venous thromboembolism in patients with transient risk factors in standard clinical practice: The FLEBUS study [7]

    Journal of Thrombosis and Haemostasis